Straight from the Desk
Syz the moment
Live feeds, charts, breaking stories, all day long.
- All
- equities
- United States
- Macroeconomics
- Food for Thoughts
- markets
- Central banks
- Fixed Income
- bitcoin
- Asia
- europe
- investing
- technical analysis
- geopolitics
- gold
- Crypto
- AI
- Commodities
- Technology
- nvidia
- ETF
- earnings
- Forex
- china
- Real Estate
- banking
- oil
- Volatility
- magnificent-7
- energy
- apple
- Alternatives
- emerging-markets
- switzerland
- tesla
- United Kingdom
- assetmanagement
- Middle East
- amazon
- russia
- ethereum
- microsoft
- ESG
- meta
- Industrial-production
- bankruptcy
- Healthcare
- Turkey
- Global Markets Outlook
- africa
- Market Outlook
- brics
New weight-loss drug ETF
“Roundhill Investments' GLP-1 & Weight Loss ETF (OZEM), which began trading last week, pairs leaders Eli Lilly and Novo Nordisk with players developing new treatments for weight loss and diabetes. CEO Dave Mazza said his firm is capitalizing on explosive growth potential in the industry…Eli Lilly and Novo Nordisk each hold a roughly 20% weighting in the ETF. The three next largest positions are Zealand Pharma, Amgen and Chugai Pharmaceutical, each of which have a weighting under 5%”. Source: CNBC, Bloomberg
Jamie Dimon does not rule out a hard landing for the US economy
Source: CNBC
The implications of an aging population for investment strategies
Source: Bloomberg
Trends in reshoring, electrification and AI are propelling US investment renaissance
Source: BNP Paribas Asset Management
Investing with intelligence
Our latest research, commentary and market outlooks

